For Institutional Investors in the US

Andy Acker, CFA

Portfolio Manager
Andy Acker, CFA | Janus Henderson Investors

Andy Acker is a Portfolio Manager at Janus Henderson Investors responsible for managing the Global Life Sciences and Biotechnology strategies since 2007 and 2018, respectively. He also leads the firm’s Health Care Sector Research Team. Mr. Acker was assistant portfolio manager on the Global Life Sciences strategy from 2003 to 2007. He joined Janus in 1999 as a research analyst focused on companies in the biotechnology and pharmaceutical industries. Prior to this, he worked as a strategy consultant for the Boston Consulting Group and as a health care analyst for Morgan Stanley Venture Partners.

Mr. Acker received his bachelor of science degree in biochemical sciences from Harvard University, graduating magna cum laude and Phi Beta Kappa. He also earned an MBA with honors from Harvard Business School. Mr. Acker holds the Chartered Financial Analyst designation and has 25 years of financial industry experience.

Articles Written

Despite Sell-Off, Health Care Fundamentals Appear Strong
Quick Views Healthcare

Despite Sell-Off, Health Care Fundamentals Appear Strong

Attractive valuations, continued innovation and an uptick in mergers and acquisitions could help lift the sector.

Drug-Pricing Reform an Uphill Battle
Quick Views Healthcare

Drug-Pricing Reform an Uphill Battle

Why the push for government-negotiated drug prices could prove to be a Sisyphean task.

Beating the Biotech Blues
Quick Views Healthcare

Beating the Biotech Blues

The sector is experiencing its worst period of relative underperformance on record. But some of history’s biggest biotech pains have been followed by memorable gains.

Innovation, Low Valuations Tailwinds for Health Care
Quick Views Healthcare

Innovation, Low Valuations Tailwinds for Health Care

Underperforming the broad market for the first half of 2021, health care now offers attractive valuations and significant growth potential, thanks to innovation.

Biopharma’s Targeted Approach to Growth
Quick Views Healthcare

Biopharma’s Targeted Approach to Growth

A new drug targeting a common mutation found in tumors represents a breakthrough in cancer therapy and a potential new source of growth for biopharma.

Making Sense of COVID-19 Vaccine IP Waivers

Making Sense of COVID-19 Vaccine IP Waivers

Why U.S. support for waiving intellectual property protections for COVID-19 vaccines does not spell the end of biotech growth.

Health care’s innovation shifts into high gear

Health care’s innovation shifts into high gear

Portfolio Manager Andy Acker explores the unprecedented number of medical breakthroughs occurring in health care and what it means for the sector.

Health Care Builds Momentum

Health Care Builds Momentum

Portfolio Manager Andy Acker says the health care sector looks set to ride a number of positive trends into 2021.